Ascendis Pharma (ASND) said Monday its new drug application for the TransCon CNP candidate to treat children with achondroplasia, a genetic condition, was accepted by the US Food and Drug Administration for priority review.
The FDA set a prescription drug user fee act date of November 30 to close the review process, according to a statement.
The US regulator is not currently planning to conduct an advisory committee meeting to discuss the application, the company said.
Shares were up 5.4% in recent trading.
Price: 171.52, Change: +8.68, Percent Change: +5.33
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。